COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies - 1st Edition - ISBN: 9780128215678, 9780128215685

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies, Volume 15

1st Edition

Editors: Ramasamy Paulmurugan Tarik Massoud
eBook ISBN: 9780128215685
Hardcover ISBN: 9780128215678
Imprint: Academic Press
Published Date: 25th June 2021
Page Count: 828
Sales tax will be calculated at check-out Price includes VAT/GST
280.86
155.00
135.00
175.00
148.75
Unavailable
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. Overview of glioblastoma biological hallmarks and molecular pathology

2. Past and present drug treatments for glioblastoma

3. Investigational new drugs against glioblastoma

4. Molecular mechanimsms in temozolomide-resistant glioblastoma

5. Glioma stem cells and associated molecular mechanisms in Glioblastoma

6. Signaling in the tumor microenvironment of therapy-resistant glioblastoma

7. Intratumoral heterogeneity associated with glioblastoma drug response and resistance

8. Role of apoptosis, autophagy, and the unfolded protein response in glioblastoma chemoresistance

9. Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters

10. Role of mitochondrial reactive oxygen species in glioblastoma drug resistance and strategies for therapeutic interventions

11. Glioblastoma cell-induced immunosuppression causing chemoresistance

12. Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention

13. The molecular and cellular effects of radiotherapy-induced microenvironment changes on potential chemoresistance in glioblastoma

14. Molecular and cellular mechanism in recurrent glioblastoma chemoresistance

15. Role of long noncoding RNAs in temozolomide-resistant glioblastoma

16. Mechanisms of glioblastoma resistance to antiangiogenic agents and reversal approaches

17. Treatment and resistance of glioblastoma to CAR T-cell immunotherapies

18. On chip analysis of glioblastoma cell chemoresistance

19. Three-dimensional in vitro models to study potentiation of glioblastoma resistance by hypoxia

20. Chemoresistance mechanisms in mouse models of glioblastoma

21. Therapeutic approaches to overcome temozolomide resistance in glioblastoma

22. Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma

23. Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy

24. Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy

25. Role of microRNA therapy in presensitizing glioblastoma cells to temozolomide treatment

26. Drug penetration through the blood-brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance

27. Nanoparticles beyond the blood-brain barrier for glioblastoma

28. Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve glioblastoma chemotherapy

29. p53 supplementation as a targeted cancer gene therapy for glioblastoma


Description

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field.

Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood.

Key Features

  • Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance
  • Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance
  • Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Readership

Cancer researchers, medical scientists, clinicians, graduate students. Neuro-oncologists


Details

No. of pages:
828
Language:
English
Copyright:
© Academic Press 2021
Published:
25th June 2021
Imprint:
Academic Press
eBook ISBN:
9780128215685
Hardcover ISBN:
9780128215678

Ratings and Reviews


About the Editors

Ramasamy Paulmurugan

Dr. Paulmurugan has expertise in molecular imaging, pre-clinical cancer imaging, cancer biology, nanotechnology, and molecular biotechnology.

Affiliations and Expertise

Associate Professor, Molecular Imaging Program at Stanford, and Department of Radiology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA

Tarik Massoud

Dr. Massoud has expertise in molecular imaging, translational cancer imaging, neuro-oncology, and applications and perspectives relevant to clinical cancer management of glioblastoma patients.

Affiliations and Expertise

Professor, Molecular Imaging Program at Stanford, and Department of Radiology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA